

L9 ANSWER 41 OF 89 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
AN 90-221170 [29] WPIDS
DNN N90-171482 DNC C90-095460

TI Monoclonal antibody for determining pancreatic **lipase** -
contains **antibody** reacting with human pancreatic
lipase without hindering **lipase** activity, and
antibody which does hinder lipase activity.

DC B04 D16 S03

PA (KOKU-N) KOKUSAI SHIYAKU KK

CYC 1

PI JP 02150294 A 900608 (9029)*

JP 07045520 B2 950517 (9524) 11 pp

ADT JP 02150294 A JP 89-188172 890719; JP 07045520 B2 JP 89-188172
890719

FDT JP 07045520 B2 Based on JP 02150294

PRAI JP 88-217192 880831; JP 89-188172 890719

AB JP02150294 A UPAB: 930928

A monoclonal antibody comprises that which reacts specifically with human pancreatic lipase but does not hinder the enzymatic activity of lipase at all and that which reacts with human pancreatic lipase and hinders specifically the enzymatic activity of human pancreatic lipase.

Determining human pancreatic **lipase** comprises **treating** simultaneously a solid phase on which the monoclonal **antibody** is immobilised, a sample and an enzyme-labelled antibody of the monoclonal antibody, removing the unreacted labelled antibody and measuring the enzymatic activity of the solid phase, or **treating** a sample with a solid phase on which the monoclonal antibody is immobilised, removing antigen in the unreacted sample, **treating** the solid phase with an enzyme-labelled antibody of the monoclonal antibody, removing the unreacted labelled antibody and measuring the enzymatic activity of the solid phase.

USE/ADVANTAGE - Useful for determining human pancreatic lipase, with high sensitivity and high reproducibility by enzyme-linked immunosorbent assay using a combination of the anti-human pancreatic **lipase** monoclonal **antibody** and the anti-human pancreatic **lipase** enzymatic activity-hindering monoclonal **antibody**.

0/0

L

NSWER 75 OF 89 BIOSIS COPYRIGHT 1998 BIOSIS DUPLICATE 30
AN 81:266025 BIOSIS
DN BA72:51009
TI ACCUMULATION OF INTERMEDIATE DENSITY LIPO PROTEIN IN PLASMA AFTER
INTRA VENOUS ADMINISTRATION OF HEPATIC TRI GLYCERIDE **LIPASE**
ANTIBODY IN RATS.
AU MURASE T; ITAKURA H
CS THIRD DEP. OF INTERNAL MED., UNIV. OF TOKYO, HONGO, TOKYO 113, JAPAN.
SO ATHEROSCLEROSIS 39 (3). 1981. 293-300. CODEN: ATHSBL ISSN: 0021-9150
LA English
AB To define the role of hepatic triglyceride **lipase** in plasma
lipoprotein metabolism, *in vivo* experiments using an **antibody**
specifically prepared against this enzyme were conducted in rats. The
antibody .gamma.-globulins were injected into rats 3 times during a
40-min period. Control rats received non-immune rabbit
.gamma.-globulins prepared in the same way as the immune
.gamma.-globulins. After **treatment** blood was taken and the
plasma was separated. Plasma lipoproteins were fractionated by
ultracentrifugation into VLDL [very low density lipoprotein],
I[intermediate]DL, LDL and H[high]DL. **Treatment** of
recipient rats with the antibody significantly increased cholesterol,
phospholipid and protein concentrations in the IDL fraction. These
concentrations were elevated in the LDL fraction. This increase may
represent the accumulation of small remnants rather than bona fide
LDL. VLDL compositions in antibody-**treated** rats did not
differ from those in control animals. In HDL the phospholipid level
was elevated in antibody-**treated** rats. Hepatic triglyceride
lipase apparently mediates the catabolism of remnant lipoproteins by
the liver.

QRI.A85

4 ANSWER 18 OF 24 ANABSTR COPYRIGHT 1998 RSC

AN 52(5):D135 ANABSTR

TI Application of two monoclonal antibodies to either an immunosorbent enzyme assay or a competitive binding enzyme immunoassay for human serum **pancreatic lipase**.

AU Ohkaro, Y.; Kurooka, S.; Kitamura, T. (Res. Lab., Dainippon Pharmaceutical Co. Ltd., Osaka 564, Japan)

SO Clin. Chim. Acta (1989) 182(3), 295-300
CODEN: CCATAR ISSN: 0009-8981

DT Journal

LA English

AB Two monoclonal **antibodies** were raised against **pancreatic triacylglycerol lipase**. One, which partially inhibited the **lipase** and which also bound enzyme-labelled lipase competitively, was used as the first antibody in a competitive enzyme immunoassay with .beta.-galactosidase as labelling enzyme and rabbit anti-mouse IgG as second antibody; galactosidase was assayed fluorimetrically. The detection limit was 1 ng ml.⁻¹ and recovery was 93.3 to 102.0%. The second **antibody**, which did not inhibit the **lipase** nor bind enzyme-labelled lipase competitively, was used as the insolubilized antibody in a spectrophotometric immunosorbent assay. From 25 to 700 ng ml.⁻¹ could be assayed. The coeff. of variation were 2.5 to 13.9% (n = 10).

CC *D Biochemistry (83000)

IT Analyte(s):

9001-62-1, triacylglycerol lipase
(assay of pancreatic, in serum, by enzyme immunoassay)

Matrix:

blood serum
(assay of **pancreatic triacylglycerol lipase** in,
by enzyme immunoassay)